Report Detail

Pharma & Healthcare Global RNA-Targeted Small Molecules Market Size, Status and Forecast 2020-2026

  • RnM4271897
  • |
  • 27 December, 2020
  • |
  • Global
  • |
  • 98 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Market Analysis by Approaches
    • 1.3.1 Global RNA-Targeted Small Molecules Market Size Growth Rate by Approaches: 2020 VS 2026
    • 1.3.2 mRNA Translation Regulation
    • 1.3.3 RNA Splicing Modification
    • 1.3.4 Direct RNA Targeting
    • 1.3.5 Indirect RNA Targeting - Epitranscriptomics
  • 1.4 Market by Application
    • 1.4.1 Global RNA-Targeted Small Molecules Market Share by Application: 2020 VS 2026
    • 1.4.2 Hospitals
    • 1.4.3 Laboratories
    • 1.4.4 Phamacy
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Global Growth Trends

  • 2.1 Global RNA-Targeted Small Molecules Market Perspective (2015-2026)
  • 2.2 RNA-Targeted Small Molecules Growth Trends by Regions
    • 2.2.1 RNA-Targeted Small Molecules Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 RNA-Targeted Small Molecules Historic Market Share by Regions (2015-2020)
    • 2.2.3 RNA-Targeted Small Molecules Forecasted Market Size by Regions (2021-2026)
  • 2.3 RNA-Targeted Small Molecules Industry Dynamic
    • 2.3.1 RNA-Targeted Small Molecules Market Trends
    • 2.3.2 RNA-Targeted Small Molecules Market Drivers
    • 2.3.3 RNA-Targeted Small Molecules Market Challenges
    • 2.3.4 RNA-Targeted Small Molecules Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top RNA-Targeted Small Molecules Players by Market Size
    • 3.1.1 Global Top RNA-Targeted Small Molecules Players by Revenue (2015-2020)
    • 3.1.2 Global RNA-Targeted Small Molecules Revenue Market Share by Players (2015-2020)
  • 3.2 Global RNA-Targeted Small Molecules Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by RNA-Targeted Small Molecules Revenue
  • 3.4 Global RNA-Targeted Small Molecules Market Concentration Ratio
    • 3.4.1 Global RNA-Targeted Small Molecules Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by RNA-Targeted Small Molecules Revenue in 2019
  • 3.5 Key Players RNA-Targeted Small Molecules Area Served
  • 3.6 Key Players RNA-Targeted Small Molecules Product Solution and Service
  • 3.7 Date of Enter into RNA-Targeted Small Molecules Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 RNA-Targeted Small Molecules Breakdown Data by Approaches

  • 4.1 Global RNA-Targeted Small Molecules Historic Market Size by Approaches (2015-2020)
  • 4.2 Global RNA-Targeted Small Molecules Forecasted Market Size by Approaches (2021-2026)

5 RNA-Targeted Small Molecules Breakdown Data by Application

  • 5.1 Global RNA-Targeted Small Molecules Historic Market Size by Application (2015-2020)
  • 5.2 Global RNA-Targeted Small Molecules Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America RNA-Targeted Small Molecules Market Size (2015-2026)
  • 6.2 North America RNA-Targeted Small Molecules Market Size by Approaches (2015-2020)
  • 6.3 North America RNA-Targeted Small Molecules Market Size by Application (2015-2020)
  • 6.4 North America RNA-Targeted Small Molecules Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe RNA-Targeted Small Molecules Market Size (2015-2026)
  • 7.2 Europe RNA-Targeted Small Molecules Market Size by Approaches (2015-2020)
  • 7.3 Europe RNA-Targeted Small Molecules Market Size by Application (2015-2020)
  • 7.4 Europe RNA-Targeted Small Molecules Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific RNA-Targeted Small Molecules Market Size (2015-2026)
  • 8.2 Asia-Pacific RNA-Targeted Small Molecules Market Size by Approaches (2015-2020)
  • 8.3 Asia-Pacific RNA-Targeted Small Molecules Market Size by Application (2015-2020)
  • 8.4 Asia-Pacific RNA-Targeted Small Molecules Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia

9 Latin America

  • 9.1 Latin America RNA-Targeted Small Molecules Market Size (2015-2026)
  • 9.2 Latin America RNA-Targeted Small Molecules Market Size by Approaches (2015-2020)
  • 9.3 Latin America RNA-Targeted Small Molecules Market Size by Application (2015-2020)
  • 9.4 Latin America RNA-Targeted Small Molecules Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa RNA-Targeted Small Molecules Market Size (2015-2026)
  • 10.2 Middle East & Africa RNA-Targeted Small Molecules Market Size by Type (2015-2020)
  • 10.3 Middle East & Africa RNA-Targeted Small Molecules Market Size by Application (2015-2020)
  • 10.4 Middle East & Africa RNA-Targeted Small Molecules Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE

11Key Players Profiles

  • 11.1 Accent Therapeutics
    • 11.1.1 Accent Therapeutics Company Details
    • 11.1.2 Accent Therapeutics Business Overview
    • 11.1.3 Accent Therapeutics RNA-Targeted Small Molecules Introduction
    • 11.1.4 Accent Therapeutics Revenue in RNA-Targeted Small Molecules Business (2015-2020))
    • 11.1.5 Accent Therapeutics Recent Development
  • 11.2 Anima Biotech Inc.
    • 11.2.1 Anima Biotech Inc. Company Details
    • 11.2.2 Anima Biotech Inc. Business Overview
    • 11.2.3 Anima Biotech Inc. RNA-Targeted Small Molecules Introduction
    • 11.2.4 Anima Biotech Inc. Revenue in RNA-Targeted Small Molecules Business (2015-2020)
    • 11.2.5 Anima Biotech Inc. Recent Development
  • 11.3 Arrakis Pharmaceuticals
    • 11.3.1 Arrakis Pharmaceuticals Company Details
    • 11.3.2 Arrakis Pharmaceuticals Business Overview
    • 11.3.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecules Introduction
    • 11.3.4 Arrakis Pharmaceuticals Revenue in RNA-Targeted Small Molecules Business (2015-2020)
    • 11.3.5 Arrakis Pharmaceuticals Recent Development
  • 11.4 Epics Therapeutics
    • 11.4.1 Epics Therapeutics Company Details
    • 11.4.2 Epics Therapeutics Business Overview
    • 11.4.3 Epics Therapeutics RNA-Targeted Small Molecules Introduction
    • 11.4.4 Epics Therapeutics Revenue in RNA-Targeted Small Molecules Business (2015-2020)
    • 11.4.5 Epics Therapeutics Recent Development
  • 11.5 Expansion Therapeutics
    • 11.5.1 Expansion Therapeutics Company Details
    • 11.5.2 Expansion Therapeutics Business Overview
    • 11.5.3 Expansion Therapeutics RNA-Targeted Small Molecules Introduction
    • 11.5.4 Expansion Therapeutics Revenue in RNA-Targeted Small Molecules Business (2015-2020)
    • 11.5.5 Expansion Therapeutics Recent Development
  • 11.6 Gotham Therapeutics
    • 11.6.1 Gotham Therapeutics Company Details
    • 11.6.2 Gotham Therapeutics Business Overview
    • 11.6.3 Gotham Therapeutics RNA-Targeted Small Molecules Introduction
    • 11.6.4 Gotham Therapeutics Revenue in RNA-Targeted Small Molecules Business (2015-2020)
    • 11.6.5 Gotham Therapeutics Recent Development
  • 11.7 H3 Biomedicine
    • 11.7.1 H3 Biomedicine Company Details
    • 11.7.2 H3 Biomedicine Business Overview
    • 11.7.3 H3 Biomedicine RNA-Targeted Small Molecules Introduction
    • 11.7.4 H3 Biomedicine Revenue in RNA-Targeted Small Molecules Business (2015-2020)
    • 11.7.5 H3 Biomedicine Recent Development
  • 11.8 Ribometrix
    • 11.8.1 Ribometrix Company Details
    • 11.8.2 Ribometrix Business Overview
    • 11.8.3 Ribometrix RNA-Targeted Small Molecules Introduction
    • 11.8.4 Ribometrix Revenue in RNA-Targeted Small Molecules Business (2015-2020)
    • 11.8.5 Ribometrix Recent Development
  • 11.9 Skyhawk Therapeutics
    • 11.9.1 Skyhawk Therapeutics Company Details
    • 11.9.2 Skyhawk Therapeutics Business Overview
    • 11.9.3 Skyhawk Therapeutics RNA-Targeted Small Molecules Introduction
    • 11.9.4 Skyhawk Therapeutics Revenue in RNA-Targeted Small Molecules Business (2015-2020)
    • 11.9.5 Skyhawk Therapeutics Recent Development
  • 11.10 STORM Therapeutics
    • 11.10.1 STORM Therapeutics Company Details
    • 11.10.2 STORM Therapeutics Business Overview
    • 11.10.3 STORM Therapeutics RNA-Targeted Small Molecules Introduction
    • 11.10.4 STORM Therapeutics Revenue in RNA-Targeted Small Molecules Business (2015-2020)
    • 11.10.5 STORM Therapeutics Recent Development
  • 11.11 Twentyeight-Seven Therapeutics
    • 10.11.1 Twentyeight-Seven Therapeutics Company Details
    • 10.11.2 Twentyeight-Seven Therapeutics Business Overview
    • 10.11.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Introduction
    • 10.11.4 Twentyeight-Seven Therapeutics Revenue in RNA-Targeted Small Molecules Business (2015-2020)
    • 10.11.5 Twentyeight-Seven Therapeutics Recent Development

12Analyst's Viewpoints/Conclusions

    13Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    RNA-Targeted Small Molecules market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global RNA-Targeted Small Molecules market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Approaches and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Approaches, the product can be split into
    mRNA Translation Regulation
    RNA Splicing Modification
    Direct RNA Targeting
    Indirect RNA Targeting - Epitranscriptomics

    Market segment by Application, split into
    Hospitals
    Laboratories
    Phamacy

    Based on regional and country-level analysis, the RNA-Targeted Small Molecules market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    In the competitive analysis section of the report, leading as well as prominent players of the global RNA-Targeted Small Molecules market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Accent Therapeutics
    Anima Biotech Inc.
    Arrakis Pharmaceuticals
    Epics Therapeutics
    Expansion Therapeutics
    Gotham Therapeutics
    H3 Biomedicine
    Ribometrix
    Skyhawk Therapeutics
    STORM Therapeutics


    Summary:
    Get latest Market Research Reports on RNA-Targeted Small Molecules. Industry analysis & Market Report on RNA-Targeted Small Molecules is a syndicated market report, published as Global RNA-Targeted Small Molecules Market Size, Status and Forecast 2020-2026. It is complete Research Study and Industry Analysis of RNA-Targeted Small Molecules market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,900.00
    $5,850.00
    $7,800.00
    2,851.52
    4,277.27
    5,703.03
    3,204.28
    4,806.41
    6,408.55
    404,804.40
    607,206.60
    809,608.80
    284,756.55
    427,134.83
    569,513.10
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report